Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa with Gemcitabine and Cisplatin in 1st-line Biliary Tract Cancer
NCT04066491Phase 3Terminated
- Sponsor
- EMD Serono
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of bintrafusp alfa in biliary tract cancer (BTC), sponsored by EMD Serono. Started Sep 2019; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04066491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066491.